Based on the provided sources, there is limited information available regarding the potential side effects of lurbinectedin on breastfeeding. None of the sources specifically mention the effects of lurbinectedin on breastfeeding, which suggests that there may not be sufficient data or studies conducted on this specific topic.

It is important to note that lurbinectedin is a relatively new drug, and its use and potential side effects are still being studied. The drug is primarily used for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received other types of chemotherapy [1].

The drug patent watch website does not provide any information on the side effects of lurbinectedin [1]. Similarly, the Mayo Clinic's drug information page on lurbinectedin does not mention breastfeeding or its potential effects on nursing infants [2].

The FDA's drug label for lurbinectedin does not provide specific information on the drug's effects on breastfeeding either [3]. However, it is important to note that drug labels often include a general precautionary statement advising against the use of the drug during breastfeeding unless the potential benefits outweigh the potential risks.

Given the lack of specific information on lurbinectedin's effects on breastfeeding, it is advisable for breastfeeding individuals to consult their healthcare provider before using this medication. Healthcare professionals can provide personalized advice based on the individual's medical history, the specific condition being treated, and the potential risks and benefits of using lurbinectedin while breastfeeding.

In conclusion, based on the provided sources, there is limited information available regarding the potential side effects of lurbinectedin on breastfeeding. It is recommended to consult with a healthcare professional for personalized advice on the use of lurbinectedin while breastfeeding.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from: https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] Mayo Clinic. Lurbinectedin (Intravenous Route) - Side Effects. Retrieved from: https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1
[3] U.S. Food and Drug Administration. Lurbinectedin (Zepzelca) Prescribing Information. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf